Literature DB >> 3304410

A study of aqueous and serum levels of ceftazidime following subconjunctival administration.

D B Clements, V Tailor.   

Abstract

Patients undergoing cataract surgery may develop an infective endophthalmitis postoperatively which may result in the loss of an eye. This study was carried out to measure aqueous humour levels and to assess patients' tolerance of ceftazidime, a potent antipseudomonal cephalosporin, given subconjunctivally. Eighteen patients received 125 mg ceftazidime subconjunctivally before they underwent routine cataract surgery. A further two patients received 62.5 mg subconjunctivally. The results show good penetration into the aqueous humour well above the minimum inhibitory concentrations (MICs) of possible pathogens. There were no postoperative infections, no local irritation, and no systemic side effects.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3304410      PMCID: PMC1041193          DOI: 10.1136/bjo.71.6.433

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  8 in total

1.  Soframycin: its penetration into the eye and its effect upon experimentally produced Staph. aureus and Ps. pyocyanea corneal infections.

Authors:  D AINSLIE; W G HENDERSON
Journal:  Br J Ophthalmol       Date:  1958-09       Impact factor: 4.638

2.  Post-operative bacterial endophthalmitis.

Authors:  S I Davidson
Journal:  Trans Ophthalmol Soc U K       Date:  1985

Review 3.  Antimicrobial drug delivery to the eye.

Authors:  T S Lesar; R G Fiscella
Journal:  Drug Intell Clin Pharm       Date:  1985-09

4.  Factors affecting the intraocular penetration of antibiotics. The influence of route, inflammation, animal species and tissue pigmentation.

Authors:  M Barza
Journal:  Scand J Infect Dis Suppl       Date:  1978

5.  Penetration of ceftazidime into the normal rabbit and human eye.

Authors:  R A Walstad; S Blika
Journal:  Scand J Infect Dis Suppl       Date:  1985

6.  Ceftazidime concentrations in human aqueous humor.

Authors:  J L Axelrod; R S Kochman; M A Horowitz; L Youngworth
Journal:  Arch Ophthalmol       Date:  1984-06

7.  Management of infectious endophthalmitis.

Authors:  R K Forster; R L Abbott; H Gelender
Journal:  Ophthalmology       Date:  1980-04       Impact factor: 12.079

8.  Tobramycin levels in aqueous humor after subconjunctival injection in humans.

Authors:  T B Gorden; R D Cunningham
Journal:  Am J Ophthalmol       Date:  1982-01       Impact factor: 5.258

  8 in total
  6 in total

1.  Ocular penetration and efficacy of levofloxacin using different drug-delivery techniques for the prevention of endophthalmitis in rabbit eyes with posterior capsule rupture.

Authors:  Takahiro Uda; Takashi Suzuki; Arisa Mitani; Yoshitaka Tasaka; Shiro Kawasaki; Tsuyoshi Mito; Yuichi Ohashi
Journal:  J Ocul Pharmacol Ther       Date:  2014-01-11       Impact factor: 2.671

Review 2.  Prophylaxis of postoperative endophthalmitis following cataract surgery: current status and future directions.

Authors:  Robert E Fintelmann; Ayman Naseri
Journal:  Drugs       Date:  2010-07-30       Impact factor: 9.546

3.  Randomised single blind trial to compare the toxicity of subconjunctival gentamicin and cefuroxime in cataract surgery.

Authors:  C D Jenkins; P J McDonnell; D J Spalton
Journal:  Br J Ophthalmol       Date:  1990-12       Impact factor: 4.638

4.  Comparative intraocular penetration of topical and injected cefuroxime.

Authors:  C D Jenkins; S J Tuft; G Sheraidah; D A McHugh; R J Buckley
Journal:  Br J Ophthalmol       Date:  1996-08       Impact factor: 4.638

5.  Influence of drug lipophilicity on drug release from sclera after iontophoretic delivery of mixed micellar carrier system to human sclera.

Authors:  Poonam Chopra; Jinsong Hao; S Kevin Li
Journal:  J Pharm Sci       Date:  2012-11-13       Impact factor: 3.534

6.  Antimicrobial pharmacokinetics in endophthalmitis treatment: studies of ceftazidime.

Authors:  T A Meredith
Journal:  Trans Am Ophthalmol Soc       Date:  1993
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.